Literature DB >> 6644555

Evaluation of methods for estimating population pharmacokinetic parameters. III. Monoexponential model: routine clinical pharmacokinetic data.

L B Sheiner, S L Beal.   

Abstract

Individual pharmacokinetic parameters quantify the pharmacokinetics of an individual, while population pharmacokinetic parameters quantify population mean kinetics, interindividual kinetic variability, and residual variability, including intraindividual variability and measurement error. Individual pharmacokinetics are estimated by fitting a pharmacokinetic model to individual data. Population pharmacokinetic parameters have traditionally been estimated by doing this separately for each individual, and then combining the individual parameter estimates, the Standard Two Stage (STS) approach. Another approach, NONMEM, appropriately pools data across individuals and is therefore less dependent on individual parameter estimates. This study provides further evidence of NONMEM's validity and usefulness by comparing both approaches on simulated routine-type pharmacokinetic data arising from a monoexponential model. The estimates of population parameters (notably those describing interindividual variability) provided by the STS method are poorer than those provided by NONMEM, especially when there is considerable residual error. Further, NONMEM's estimates of population parameters do not require that the data be restricted to special types of routine data such as those obtained only at steady state, or only at peak or trough, nor do the estimates improve with such data. NONMEM's estimates do improve, however, when a data set is enhanced by the addition of single-observation-per-individual type data. Thus, population parameters can be estimated efficiently from data that simulate real clinical pharmacokinetic conditions.

Mesh:

Substances:

Year:  1983        PMID: 6644555     DOI: 10.1007/BF01061870

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  4 in total

1.  Estimation of population characteristics of pharmacokinetic parameters from routine clinical data.

Authors:  L B Sheiner; B Rosenberg; V V Marathe
Journal:  J Pharmacokinet Biopharm       Date:  1977-10

2.  Forecasting individual pharmacokinetics.

Authors:  L B Sheiner; S Beal; B Rosenberg; V V Marathe
Journal:  Clin Pharmacol Ther       Date:  1979-09       Impact factor: 6.875

3.  Evaluation of methods for estimating population pharmacokinetic parameters. II. Biexponential model and experimental pharmacokinetic data.

Authors:  L B Sheiner; S L Beal
Journal:  J Pharmacokinet Biopharm       Date:  1981-10

4.  Evaluation of methods for estimating population pharmacokinetics parameters. I. Michaelis-Menten model: routine clinical pharmacokinetic data.

Authors:  L B Sheiner; S L Beal
Journal:  J Pharmacokinet Biopharm       Date:  1980-12
  4 in total
  74 in total

1.  Impact of pharmacokinetic-pharmacodynamic model linearization on the accuracy of population information matrix and optimal design.

Authors:  Y Merlé; M Tod
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-08       Impact factor: 2.745

2.  Is mixed effects modeling or naïve pooled data analysis preferred for the interpretation of single sample per subject toxicokinetic data?

Authors:  J P Hing; S G Woolfrey; D Greenslade; P M Wright
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-04       Impact factor: 2.745

3.  Smooth nonparametric maximum likelihood estimation for population pharmacokinetics, with application to quinidine.

Authors:  M Davidian; A R Gallant
Journal:  J Pharmacokinet Biopharm       Date:  1992-10

4.  A computationally efficient approach for the design of population pharmacokinetic studies.

Authors:  J Wang; L Endrenyi
Journal:  J Pharmacokinet Biopharm       Date:  1992-06

5.  Anticoagulation therapy advisor: a decision-support system for heparin therapy during ECMO.

Authors:  R L Peverini; M Sale; W D Rhine; L M Fagan; L A Lenert
Journal:  Proc Annu Symp Comput Appl Med Care       Date:  1992

6.  Performance comparison of various maximum likelihood nonlinear mixed-effects estimation methods for dose-response models.

Authors:  Elodie L Plan; Alan Maloney; France Mentré; Mats O Karlsson; Julie Bertrand
Journal:  AAPS J       Date:  2012-04-14       Impact factor: 4.009

7.  Experimental design and efficient parameter estimation in population pharmacokinetics.

Authors:  M K al-Banna; A W Kelman; B Whiting
Journal:  J Pharmacokinet Biopharm       Date:  1990-08

8.  Covariance analysis of laboratory variance in steady-state serum phenytoin concentrations.

Authors:  H Costeff; Z Groswasser; N Soroker; G van Belle
Journal:  Clin Pharmacokinet       Date:  1991-04       Impact factor: 6.447

9.  An evaluation of point and interval estimates in population pharmacokinetics using NONMEM analysis.

Authors:  D B White; C A Walawander; Y Tung; T H Grasela
Journal:  J Pharmacokinet Biopharm       Date:  1991-02

Review 10.  Interpreting population pharmacokinetic-pharmacodynamic analyses - a clinical viewpoint.

Authors:  Stephen B Duffull; Daniel F B Wright; Helen R Winter
Journal:  Br J Clin Pharmacol       Date:  2011-06       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.